Lynch Asset Management Inc. Acquires Shares of 1,000 Eli Lilly and Company $LLY

Lynch Asset Management Inc. acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, Holdings Channel reports. The firm acquired 1,000 shares of the company’s stock, valued at approximately $763,000.

A number of other institutional investors also recently made changes to their positions in the business. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth $27,000. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. increased its holdings in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company during the second quarter valued at approximately $31,000. Finally, Bare Financial Services Inc lifted its holdings in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Finally, Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a research note on Monday, January 5th. Five research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $1,169.00.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Nvidia co‑innovation AI lab — Nvidia and Lilly will commit up to $1 billion over five years to a San Francisco‑area AI drug discovery lab that will run Nvidia’s newest Vera Rubin AI chips; the partnership could speed candidate discovery, improve R&D productivity and lower time‑to‑market for future programs. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Management says orforglipron supply is ready — Lilly told investors it’s confident in pill supply ahead of expected U.S. approval, reducing a near‑term execution risk that would otherwise pressure launches and early sales. Lilly says it’s confident weight-loss pill supply ahead of U.S. approval
• Positive Sentiment: Ventyx acquisition adds inflammation program that could complement GLP‑1 franchise — Investors cheered Lilly’s deal for Ventyx (adds VTX3232 data showing inflammation benefit with GLP‑1), which could become an add‑on therapy and extend addressable market for Lilly’s weight‑loss/diabetes drugs.
• Neutral Sentiment: Aktis Oncology stake and biotech deal exposure — Lilly anchored Aktis’ IPO and holds a meaningful equity/stake that gives exposure to targeted radiopharma programs; strategic but long‑dated and dependent on clinical milestones. Aktis Oncology aims to raise up to $317.7 million in IPO
• Neutral Sentiment: Analyst/coverage pieces highlight growth case and new tech investments — Multiple outlets and analysts are reiterating Lilly’s growth story (tirzepatide momentum, pipeline upside) and noting Lilly is building advanced compute/supercomputer capacity; that supports a bullish narrative but is forward‑looking. Here’s Why Eli Lilly (LLY) is a Strong Growth Stock
• Negative Sentiment: Competition from Novo Nordisk’s Wegovy Pill — Novo’s U.S. roll‑out of an oral Wegovy competitor raises market‑share risk for Lilly’s upcoming orforglipron launch and is a clear near‑term competitive headwind priced by investors. Novo Nordisk launches Wegovy Pill in the U.S.

Eli Lilly and Company Trading Up 1.6%

Shares of NYSE:LLY opened at $1,080.92 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company’s 50-day moving average price is $1,040.85 and its 200 day moving average price is $863.67. The company has a market cap of $1.02 trillion, a PE ratio of 52.88, a P/E/G ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.